University of Chicago Medicine Comprehensive Cancer Center | Strategic Alliance Partners

Daniel Olson, MD, discusses findings with brenetafusp from a phase 1/2 trial (NCT04262466) in patients with advanced melanoma.

Frederick Howard, MD, outlines limitations and opportunities for AI in breast pathology, shifting focus from workflow efficiency to prognostic value.

Sonali M. Smith, MD, discusses implications of data for tafasitamab plus lenalidomide/R-CHOP in high-risk diffuse large B-cell lymphoma.

Nan Chen, MD, discusses ADC-associated toxicity management in breast cancer, as well as the evolving role of oral SERDs in ER-positive disease.

Heather Leeper, MD, discussed ideal survivorship care for geriatric patients with brain cancer.

Experts highlight some top hematologic oncology data presented at ASCO 2026, including from key studies in multiple myeloma and diffuse large B-cell lymphoma.

Wendy Stock, MD, details key recommendations from the 2026 ASH guidelines for adolescent/young adult acute lymphoblastic leukemia management.

Jessica Donington, MD, MSCR, discusses how the availability of targeted therapy has affected surgical decision-making in early-stage lung cancer.

The top 5 OncLive TV videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, lung cancer, breast cancer, and prostate cancer.

Rita Nanda, MD, discusses important research that has been conducted by the Translational Breast Cancer Research Consortium.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss which future advances being examined in clinical trials in gynecologic oncology are catching their eyes.

Rita Nanda, MD, discusses the I-SPY 2 study in patients with breast cancer.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss the most interesting recent trends in clinical trials in gynecologic oncology.

Wendy Stock, MD, discusses recommendations from the ASH Guidelines on utilizing pediatric-inspired regimens in adolescent/young adult ALL.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss their approaches to supporting patients with gynecologic malignancies during clinical trials.

Rita Nanda, MD, discusses the importance of clinical trials in breast cancer.

Sonali Smith, MD, discusses CAR-T cell therapies moving into solid tumors, the role of clinical trials in hematologic oncology, and the rising incidence of certain cancers in young adults.

Alexander T. Pearson, MD, PhD, discusses the role of AI for clinical trial design and enrollment.

John Moroney, MD, and Katherine Kurnit, MD, MPH, emphasize the importance of timing in gynecologic cancer clinical trials.

Alexander T. Pearson, MD, PhD, discusses how AI can be used for oncologic drug discovery and development.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss how they go about determining which patients are suitable candidates for clinical trials.

Alexander T. Pearson, MD, PhD, discusses how he uses AI in his current daily practice.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss the importance of clinical trials in gynecologic oncology.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

Alexandra Rojek, MD, discusses efforts to improve the safety and efficacy of CAR T-cell therapies in lymphoma through ongoing research.

Stacy Tessler Lindau, MD, MA, discusses potential next steps for the Bionic Breast project.

Sonali M. Smith, MD, discusses efforts to translate benefit with CAR T-cell therapy from hematologic malignancies to the solid tumor space.

Stacy Tessler Lindau, MD, MA, discusses which patients would be strong fits for the Bionic Breast project.

Stacy Tessler Lindau, MD, MA, discusses the design of the Bionic Breast project at University of Chicago.